Clinical Trials Logo

Stage IIIb Lung Cancer clinical trials

View clinical trials related to Stage IIIb Lung Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04005144 Terminated - Clinical trials for Lung Non-Small Cell Carcinoma

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Start date: February 25, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01228435 Terminated - Lung Cancer Clinical Trials

IPI-504 in NSCLC Patients With ALK Translocations

Start date: October 2010
Phase: Phase 2
Study type: Interventional

IPI-504 blocks a protein that is in cancer cells and is also in normal cells. This protein is called Heat Shock Protein-90 (Hsp90). Hsp90 helps protect certain other proteins from being destroyed by cells. These proteins can mutate to give off signals that allow cancer cells to keep growing. By blocking the function of Hsp90, we hope that the cancer cell will block the mutated protein and cause the cancer cells to die. This drug have been used in other research studies and in the laboratory and information from those other research studies suggests that thsi drug may help to treat lung cancer with ALK mutations. In this research study, we are looking to see what effects IPI-504 has in patients with lung cancer who have an ALK mutation.